ASX:PMEHealthcare Services
Is Fairmont’s Sell Call Reframing Pro Medicus’ (ASX:PME) High-Valuation Healthcare Tech Narrative?
In early April 2026, Fairmont Equities issued a sell rating on Pro Medicus, highlighting concerns about technology stock rotation and uncertainty around the company’s high valuation amid market volatility and higher interest rates.
The move underscores how macro factors such as sector rotation and investor caution can heavily influence sentiment toward even highly specialized healthcare technology providers like Pro Medicus.
We’ll now examine how Fairmont’s cautious stance on valuations and...